Menarini Group Completes Acquisition of Stemline Therapeutics

Menarini Group today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash consideration up to $677 million on a fully diluted basis.

First567810121314Last
Scroll Top